Dear Christoph,
Thanks, the agenda looks good. If we are too many, I don't mind not attending.
Would it be worth also asking about how many applications for plant patents are currently being examined that were submitted after July 2017, and so where Rule 28 (2) applies?
Best Katherine
-----Ursprüngliche Nachricht----- Von: Npos_2018 [mailto:npos_2018-bounces@testbiotech.de] Im Auftrag von Christoph Then Gesendet: Dienstag, 10. November 2020 18:29 An: npos_2018@testbiotech.de Betreff: [Npos_2018] ! planning for meeting with EPO
Dear all
I will propose some points for the agenda for our online meeting with the EPO on 4 of December.
the following colleagues have noted their interest in the meeting:
Johanna, Ruth, Bram, Francois, Katherine - correct?
points for the agenda could be:
(1) update from the meeting of the patent law committee and outlook to the Admin Council: Are our points taken on board? was there any substantial debate? Can we expect any decisions?
(2) follow up on the points raised in our first meeting:
2.1. can patents on random mutagenesis be excluded under current patent law or do we need a change of the EPC?
2.2. which implications will patents on cells derived from plants and animals have? how can it be excluded that patent claims are deferred to plants and animals?
2.3. how can the scope of patents be limited? Is it possible to stop absolute product protection for patents being granted under Art 53 b under current patent law or do we need a change of the EPC?
(3) are there any plans to enable participation of civil society in future meetings of the Administrative Council?
(4) outline of the further process for the ongoing exchange of arguments
I think we should ask the meeting should last longer than the first one (I propose two hours).
please let me know your comments till Thursday, if possible. Thanks!
have nice evening!
Christoph
_______________________________________________ Npos_2018 mailing list Npos_2018@testbiotech.de https://lists.testbiotech.de/cgi-bin/mailman/listinfo/npos_2018